XYZ-REALITY
16.4.2024 14:02:02 CEST | Business Wire | Press release
XYZ Reality, the leading engineering grade augmented reality (AR) platform for data center and mission critical construction, is proud to announce the appointment of data center industry veterans Christian Belady and Brian Mattson as Strategic Advisors. With their extensive experience and innovative vision, they will help guide XYZ Reality in enhancing its data center construction solution and product roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416398782/en/
Christian Belady (Photo: Business Wire)
Christian Belady, recognized as one of the "5 People who changed the data center" industry, brings a wealth of expertise in managing data center and infrastructure development at a global scale. Formerly Vice President and Distinguished Engineer at Microsoft, Belady developed one of the largest data center footprints in the world. Notably, during his tenure at Hewlett Packard, he was the innovator behind the Power Usage Effectiveness (PUE) metric. His expertise will prove invaluable to XYZ Reality's mission of building it right first time, offering crucial support in product development and sharing invaluable insights and expertise garnered from years of experience in the data center industry.
“I am thrilled to join XYZ Reality as a Strategic Advisor,” said Christian Belady. “At a time when speed to market is paramount, the company’s approach and cutting-edge technology to transforming data center construction and delivery is impressive, and I am eager to contribute to its success with our combined experience and knowledge.”
Brian Mattson brings over 40 years of experience leading large-scale global engineering and construction programs in the semiconductor and data center industries. Prior to joining XYZ Reality, Mattson served in leadership roles at Google, NTT Global Data Centers Americas, and Microsoft. His leadership at Google and Microsoft in global construction and infrastructure supply chain will contribute significantly to XYZ Reality’s growth.
"We are delighted to welcome Christian Belady and Brian Mattson to XYZ Reality as Strategic Advisors," said David Mitchell, Founder & CEO of XYZ Reality. "Their passion, expertise and innovative track record are crucial as we transform the data center industry with our Platform. This collaboration will further enhance our real-time project controls, enabling a proactive approach to construction. Their insights in the mission critical space will streamline processes and boost efficiency as we pioneer proactive solutions in this field.”
Notes to Editor
XYZ Reality is a leading developer of construction technology solutions that give owners and contractors an accurate and objective way to manage and deliver projects. Combining its Engineering Grade AR™ technology and comprehensive Project Controls solution, XYZ gives construction teams the ability to accurately build from holograms of 3D models, and proactively manage their projects with objective real-time insights. This is a revolutionary move away from a reliance on 2D drawings and subjective, out of date data, towards a future where accuracy means each project is built right, first time. The largest developers have implemented XYZ on projects totaling over $10 billion. XYZ is headquartered in London, England with offices around the globe. For more information, visit www.xyzreality.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416398782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom